Japanese Biotech Stock News

Toyo Seikan Group Holdings (TSE:5901) updated its full year earnings forecast for the period ending March 31, 2026, guiding to net sales of ¥960,000 million and profit attributable to shareholders of ¥49,000 million. See our latest analysis for Toyo Seikan Group Holdings. The revised guidance comes as Toyo Seikan Group Holdings’ share price has a 90 day share price return of 15.62%, alongside a 1 year total shareholder return of 78.41% and 5 year total shareholder return of 267.64%. This...

Tokyo Electron (TSE:8035) has drawn fresh attention after its board approved a share repurchase of up to 7,500,000 shares, together with higher earnings guidance and an increased dividend outlook for the current fiscal year. See our latest analysis for Tokyo Electron. These announcements have arrived at a time when momentum in the shares has been strong, with a 90 day share price return of 33.51% and a 1 year total shareholder return of 70.97%. This highlights how expectations around growth...

If you are wondering whether Advantest is still attractively priced after a huge run, this article will walk through what the current share price could mean for long term investors. The stock last closed at ¥26,960, with returns of 21.7% over 30 days, 27.3% year to date and 182.2% over 1 year, while the 3 year and 5 year returns are very large. Recent headlines have focused on Advantest's role in semiconductor testing equipment and its exposure to trends such as artificial intelligence...

As global markets navigate the complexities of AI disruption and fluctuating economic indicators, the Asian market presents a unique landscape for investors seeking opportunities in under-the-radar stocks. With key indices showing varied performances and economic conditions evolving, identifying a good stock often involves looking at companies with strong fundamentals that can adapt to technological changes and shifting consumer demands.

Itoham Yonekyu Holdings (TSE:2296) has come into focus after reporting nine month earnings that show higher sales and net income than a year earlier, along with raised full year guidance and a board meeting to consider a dividend. See our latest analysis for Itoham Yonekyu Holdings. The recent earnings beat, raised guidance and upcoming dividend decision sit alongside firm momentum, with a 30 day share price return of 4.55% and a 1 year total shareholder return of 76.58%, indicating...

Taikisha (TSE:1979) has drawn fresh attention after reporting nine month earnings to December 31, 2025, with higher sales and net income, and raising full year profit guidance while keeping its sales outlook unchanged. See our latest analysis for Taikisha. The earnings beat and raised profit guidance sit alongside a 12.08% year to date share price return and an 18.91% 3 month share price return, while the 1 year total shareholder return of 61.35% points to strong longer term momentum. If...

Soft earnings didn't appear to concern MarkLines Co., Ltd.'s ( TSE:3901 ) shareholders over the last week. Our analysis...

Kawasaki Heavy Industries (TSE:7012) has drawn fresh investor attention after announcing a planned stock split, higher year end dividend guidance, updated full year earnings targets, and stronger nine month results. See our latest analysis for Kawasaki Heavy Industries. The latest announcements on the stock split, higher dividend guidance and stronger nine month earnings have come after a powerful run, with a 30 day share price return of 16.30% and a year to date gain of 51.29%. The 1 year...

Celebrations may be in order for BuySell Technologies Co.,Ltd. ( TSE:7685 ) shareholders, with the analysts delivering...

Earnings trigger and why it matters now Terumo (TSE:4543) just reported record-high third quarter revenue and operating profit, backed by higher nine month sales and net income, with extra support from North America and its OrganOx acquisition. See our latest analysis for Terumo. Despite the upbeat earnings story, Terumo's share price has been under pressure, with a 90 day share price return of 17.52% and a 1 year total shareholder return of 27.41%. The 3 year total shareholder return of...

Sony Group recently reported December 2025 quarter results showing sales of ¥3,713,681 million but a net loss of ¥1,008,612 million, while also updating full‑year 2026 guidance to sales of ¥12.30 trillion, operating income of ¥1.54 trillion and net income of ¥1.13 trillion. Alongside these earnings, Sony announced a leadership reshuffle effective April 2026 and expanded its share buyback authorization, even as its technology will underpin coaching communications, broadcast imaging and...

In February 2026, JAKKS Pacific announced it had renewed its partnership with Universal Products & Experiences, Illumination and Nintendo to launch an expanded Super Mario Galaxy Movie toy line, with figures, playsets and plush now available for pre-order at major retailers including Walmart, Target and Smyths Toys. This broadened merchandise range underlines how Nintendo’s characters are being leveraged far beyond consoles, deepening fan engagement across film, toys and collectibles. We’ll...

In early February 2026, Astellas Pharma raised its full-year revenue and profit guidance, citing stronger global sales of XTANDI and Mirabegron and favorable foreign exchange effects, while also resolving all U.S. Myrbetriq patent litigation through settlements totaling US$210,000,000 in cash and license payments from Lupin and Zydus. Shortly afterward, Evinova announced an AI-powered clinical development collaboration with Astellas, AstraZeneca and Bristol Myers Squibb, highlighting...

Kubota Corporation’s board meeting on February 12, 2026 approved a year-end dividend of ¥25 per share for 2025, confirmed capital infusion of ₹5 billion into Escorts Kubota Finance, and advanced stock-based compensation plans using treasury shares. On the same day, Kubota reported full-year 2025 earnings with slightly higher sales but lower net income, while issuing 2026 guidance that includes higher dividend expectations, highlighting a continued emphasis on shareholder returns despite...

Earnings update and why it matters for Daikin IndustriesLtd (TSE:6367) Daikin IndustriesLtd (TSE:6367) is back in focus after reporting nine month earnings to December 31, 2025, alongside fresh full year guidance that gives investors a clearer view of expected sales, profit and earnings per share. See our latest analysis for Daikin IndustriesLtd. The fresh guidance and nine month update come after a period where the share price has seen a 7.70% 7 day share price return and a 28.66% 1 year...

Shareholders might have noticed that Bridgestone Corporation ( TSE:5108 ) filed its annual result this time last week...

Charm Care Corporation's ( TSE:6062 ) stock showed strength, with investors undeterred by its weak earnings report. We...

As global markets grapple with AI disruption concerns and fluctuating economic indicators, Asia presents a unique landscape where small-cap stocks are gaining attention amidst broader market shifts. In this context, identifying promising stocks involves looking for companies that demonstrate resilience and adaptability in changing environments, often characterized by innovative strategies or niche market positions.

There's been a notable change in appetite for PeptiDream Inc. ( TSE:4587 ) shares in the week since its yearly report...

The market for Toray Industries, Inc.'s ( TSE:3402 ) shares didn't move much after it posted weak earnings recently. We...

The market was pleased with the recent earnings report from Bando Chemical Industries, Ltd. ( TSE:5195 ), despite the...

What Kajima’s guidance revision and earnings update mean for investors Kajima (TSE:1812) has drawn fresh attention after raising its full year earnings guidance and reporting higher sales, revenue and net income for the nine months to December 2025, driven by construction business performance. The new consolidated forecast now points to revenues of ¥3,030,000 million, operating income of ¥228,000 million and net income attributable to owners of parent of ¥170,000 million, with basic earnings...

Earlier this month, Takeda Pharmaceutical announced that the U.S. FDA accepted its New Drug Application and granted Priority Review for orexin agonist Oveporexton (TAK-861) in narcolepsy type 1, with a PDUFA decision expected in the third quarter of this year. This development highlights Takeda’s push into orexin-targeted neuroscience, aiming to address persistent symptoms in narcolepsy type 1 where many patients remain insufficiently treated. We’ll now examine how the FDA’s Priority Review...

Hikari Tsushin (TSE:9435) drew fresh attention after reporting nine month earnings to December 31, 2025, along with higher full year profit and dividend forecasts, citing foreign exchange gains and its policy of steadily returning cash to shareholders. See our latest analysis for Hikari Tsushin. Despite the earnings and dividend guidance news, Hikari Tsushin’s recent share price has been soft, with a 7 day share price return of a 5.74% decline and a 30 day share price return of a 4.4%...